1
|
Liu N, Yang X, Guo J, Zhang L, Huang S, Chen J, Huang J, Chen Y, Cui T, Zheng Y, Li T, Tang K, Zhong Y, Duan S, Yu L, Tang Y, Zheng D, Pan H, Gao Y. Hepatic ZBTB22 promotes hyperglycemia and insulin resistance via PEPCK1-driven gluconeogenesis. EMBO Rep 2023; 24:e56390. [PMID: 37154299 PMCID: PMC10240208 DOI: 10.15252/embr.202256390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Revised: 03/31/2023] [Accepted: 04/14/2023] [Indexed: 05/10/2023] Open
Abstract
Excessive gluconeogenesis can lead to hyperglycemia and diabetes through as yet incompletely understood mechanisms. Herein, we show that hepatic ZBTB22 expression is increased in both diabetic clinical samples and mice, being affected by nutritional status and hormones. Hepatic ZBTB22 overexpression increases the expression of gluconeogenic and lipogenic genes, heightening glucose output and lipids accumulation in mouse primary hepatocytes (MPHs), while ZBTB22 knockdown elicits opposite effects. Hepatic ZBTB22 overexpression induces glucose intolerance and insulin resistance, accompanied by moderate hepatosteatosis, while ZBTB22-deficient mice display improved energy expenditure, glucose tolerance, and insulin sensitivity, and reduced hepatic steatosis. Moreover, hepatic ZBTB22 knockout beneficially regulates gluconeogenic and lipogenic genes, thereby alleviating glucose intolerance, insulin resistance, and liver steatosis in db/db mice. ZBTB22 directly binds to the promoter region of PCK1 to enhance its expression and increase gluconeogenesis. PCK1 silencing markedly abolishes the effects of ZBTB22 overexpression on glucose and lipid metabolism in both MPHs and mice, along with the corresponding changes in gene expression. In conclusion, targeting hepatic ZBTB22/PEPCK1 provides a potential therapeutic approach for diabetes.
Collapse
Affiliation(s)
- Naihua Liu
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
- Key Specialty of Clinical PharmacyThe First Affiliated Hospital of Guangdong Pharmaceutical UniversityGuangzhouChina
- Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of TumorNanjing University of Chinese MedicineNanjingJiangsu ProvinceChina
| | - Xiaoying Yang
- Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and ImmunologyXuzhou Medical UniversityXuzhouChina
| | - Jingyi Guo
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Lei Zhang
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Shangyi Huang
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Jiabing Chen
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Jiawen Huang
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Yingjian Chen
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Tianqi Cui
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Yi Zheng
- Faculty of Chinese MedicineMacau University of Science and TechnologyMacauChina
| | - Tianyao Li
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Kaijia Tang
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Yadi Zhong
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Siwei Duan
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
| | - Lili Yu
- Faculty of Chinese MedicineMacau University of Science and TechnologyMacauChina
| | - Ying Tang
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
- Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of TumorNanjing University of Chinese MedicineNanjingJiangsu ProvinceChina
| | - Dayong Zheng
- Department of HepatologyTCM‐Integrated Hospital of Southern Medical UniversityGuangzhouChina
- Department of HepatopancreatobiliaryCancer Center, Southern Medical UniversityGuangzhouChina
- Department of Oncology, The First Affiliated Hospital of Guangzhou University of Chinese MedicineGuangzhou University of Chinese MedicineGuangzhouChina
| | - Huafeng Pan
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
- Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of TumorNanjing University of Chinese MedicineNanjingJiangsu ProvinceChina
| | - Yong Gao
- Science and Technology Innovation CenterGuangzhou University of Chinese MedicineGuangzhouChina
- Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine in Prevention and Treatment of TumorNanjing University of Chinese MedicineNanjingJiangsu ProvinceChina
- Division of Hypothalamic Research, Department of Internal MedicineThe University of Texas Southwestern Medical Center at DallasTXDallasUSA
| |
Collapse
|
2
|
Ren YR, Ye YL, Feng Y, Xu TF, Shen Y, Liu J, Huang SL, Shen JH, Leng Y. SL010110, a lead compound, inhibits gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and improves glucose homeostasis in diabetic mice. Acta Pharmacol Sin 2021; 42:1834-1846. [PMID: 33574568 PMCID: PMC8563938 DOI: 10.1038/s41401-020-00609-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2020] [Accepted: 12/29/2020] [Indexed: 12/25/2022] Open
Abstract
Suppression of excessive hepatic gluconeogenesis is an effective strategy for controlling hyperglycemia in type 2 diabetes (T2D). In the present study, we screened our compounds library to discover the active molecules inhibiting gluconeogenesis in primary mouse hepatocytes. We found that SL010110 (5-((4-allyl-2-methoxyphenoxy) methyl) furan-2-carboxylic acid) potently inhibited gluconeogenesis with 3 μM and 10 μM leading to a reduction of 45.5% and 67.5%, respectively. Moreover, SL010110 caused suppression of gluconeogenesis resulted from downregulating the protein level of phosphoenolpyruvate carboxykinase 1 (PEPCK1), but not from affecting the gene expressions of PEPCK, glucose-6-phosphatase, and fructose-1,6-bisphosphatase. Furthermore, SL010110 increased PEPCK1 acetylation, and promoted PEPCK1 ubiquitination and degradation. SL010110 activated p300 acetyltransferase activity in primary mouse hepatocytes. The enhanced PEPCK1 acetylation and suppressed gluconeogenesis caused by SL010110 were blocked by C646, a histone acetyltransferase p300 inhibitor, suggested that SL010110 inhibited gluconeogenesis by activating p300. SL010110 decreased NAD+/NADH ratio, inhibited SIRT2 activity, and further promoted p300 acetyltransferase activation and PEPCK1 acetylation. These effects were blocked by NMN, an NAD+ precursor, suggested that SL010110 inhibited gluconeogenesis by inhibiting SIRT2, activating p300, and subsequently promoting PEPCK1 acetylation. In type 2 diabetic ob/ob mice, single oral dose of SL010110 (100 mg/kg) suppressed gluconeogenesis accompanied by the suppressed hepatic SIRT2 activity, increased p300 activity, enhanced PEPCK1 acetylation and degradation. Chronic oral administration of SL010110 (15 or 50 mg/kg) significantly reduced the blood glucose levels in ob/ob and db/db mice. This study reveals that SL010110 is a lead compound with a distinct mechanism of suppressing gluconeogenesis via SIRT2-p300-mediated PEPCK1 degradation and potent anti-hyperglycemic activity for the treatment of T2D.
Collapse
Affiliation(s)
- Yu-Ran Ren
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
- University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Yang-Liang Ye
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Ying Feng
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Ti-Fei Xu
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Yu Shen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Jia Liu
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
| | - Su-Ling Huang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
| | - Jian-Hua Shen
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
| | - Ying Leng
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- University of Chinese Academy of Sciences, Beijing, 100049, China.
| |
Collapse
|
3
|
Abstract
Phosphoenolpyruvate carboxykinase (PEPCK1) is ubiquitinated by E3 ubiquitin ligase UBR5, which was thought to be facilitated by the acetylation of Lys70, Lys71 and Lys594 in PEPCK1. Here, we made a series of UBR5 HECT domain truncation variants and, through pull-down assay, showed that the N-terminal lobe of the UBR5 HECT domain is largely responsible for interacting with PEPCK1. We mutated all three lysine residues thought to be acetylated in PEPCK1 but were surprised to observe no loss of binding to UBR5 HECT domain. Furthermore, two PEPCK1 truncation variants (74-622 aa and 10-560 aa) lacking these lysine residues were still able to bind with UBR5 and ubiquitinated in HEK293T cells. To discover the ubiquitination site(s) of PEPCK1, which is currently unknown, the Lys residues of PEPCK1 were mutated to Ala and the ubiquitination level of the PEPCK1 mutants was assessed. Results revealed at least two ubiquitination sites (Lys243 and Lys342), which represent the first time that ubiquitination sites of PEPCK1 have been identified. Our pull-down experiments further show that the lack of ubiquitination of PEPCK1 Lys243Ala and Lys342Ala mutants is not due to their binding to UBR5, which remained unchanged. Taken together, our work has provided new insights into UBR5 mediated ubiquitination of PEPCK1. Summary: Identification of the recruit function of the N-terminal lobe of the UBR5 HECT domain and ubiquitination site(s) of PEPCK1.
Collapse
Affiliation(s)
- Qingya Shen
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| | - Zhiyu Qiu
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| | - Wenping Wu
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| | - Jimin Zheng
- College of Chemistry, Beijing Normal University, Beijing 100875, China
| | - Zongchao Jia
- Department of Biochemical and Molecular Sciences, Queen's University, Kingston, Ontario, K7L 3N6, Canada
| |
Collapse
|
4
|
Zhang B, Pan Y, Xu L, Tang D, Dorfman RG, Zhou Q, Yin Y, Li Y, Zhou L, Zhao S, Zou X, Wang L, Zhang M. Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3. Endocrine 2018; 62:576-587. [PMID: 30117113 DOI: 10.1007/s12020-018-1689-y] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2018] [Accepted: 07/18/2018] [Indexed: 12/21/2022]
Abstract
OBJECTIVE Many studies have confirmed the glucose-lowering effect of berberine in type 2 diabetes patients. Although the mechanism of action of berberine involves the improvement of insulin sensitivity, its hypoglycemic mechanism remains elusive. Here we show a new mechanism by which berberine antagonizes glucagon signaling and find that SIRT3 is involved in the hypoglycemic effect of berberine. METHODS Gene knockout and overexpression were used to assess the inhibitory effect of berberine on SIRT3. Downstream signaling pathways and the hypoglycemic effect of SIRT3 were evaluated by immunoblotting and metabolic monitoring. RESULTS We found that berberine led to mitochondrial dysfunction and AMP accumulation by inhibiting deacetylase SIRT3. We confirmed that AMP accumulation activated the AMPK signaling pathway and further promoted glucose uptake. Simultaneously, AMP accumulation reduced cyclic AMP (cAMP) levels and abrogated the phosphorylation of critical protein targets of protein kinase A (PKA). Furthermore, we found that phosphoenolpyruvate carboxykinase 1 (PEPCK1) is a key gluconeogenesis enzyme that can be stabilized by glucagon. Berberine caused significant PEPCK1 ubiquitination and degradation by antagonizing glucagon and was accompanied by high levels of PEPCK1 acetylation. Interestingly, berberine-induced glucagon inhibition is independent of AMPK activation. The in vivo data from sirt3 knockout mice were further confirmed by the in vitro experiments. CONCLUSIONS Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting SIRT3, and regulating mitochondria-related pathways may provide a novel approach to the development of antidiabetic drugs.
Collapse
Affiliation(s)
- Bingjie Zhang
- Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China
- Department of Endocrinology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Yida Pan
- Department of Digestive Diseases of Huashan Hospital, Fudan University, Shanghai, China
| | - Lei Xu
- Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Dehua Tang
- Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China
| | | | - Qian Zhou
- School of Life Sciences, Fudan University, Shanghai, China
| | - Yuyao Yin
- Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Yang Li
- Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Lixing Zhou
- Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Shimin Zhao
- School of Life Sciences, Fudan University, Shanghai, China
- Key laboratory of Reproduction Regulation of NPFPC (SIPPR, IRD), Fudan University, Shanghai, China
| | - Xiaoping Zou
- Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China
| | - Lei Wang
- Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China.
| | - Mingming Zhang
- Department of Gastroenterology, Drum Tower hospital affiliated to Nanjing University Medical School, Nanjing University, Nanjing, China.
- School of Life Sciences, Fudan University, Shanghai, China.
- Key laboratory of Reproduction Regulation of NPFPC (SIPPR, IRD), Fudan University, Shanghai, China.
| |
Collapse
|